

SUPPLEMENTAL MATERIALS

Title: Pharmacokinetic Drug Interaction Studies of Limnetrelvir with Midazolam and Itraconazole in Healthy Participants

Janki M. Desai^{1*} PhD, Ekram Ahmed Chowdhury^{1*} PhD, Izna Ali^{1#} PhD, Christine M. Lee¹ PhD, Jeffrey M. Schmidt PhD¹, Amelia Orejudos¹ MSc, Swarna L. Yadlapalli¹ MD, Shelly Gupta¹ MD, Christopher Ocampo¹ MD, Michael G. Miller¹ PharmD, Ahmed Hamed. Salem^{1,2} PhD, FCP, Nael M. Mostafa¹ PhD

¹ AbbVie Inc., North Chicago, Illinois, USA

² Clinical Pharmacy, Ain Shams University, Cairo, Egypt.

* Both authors contributed equally to the manuscript.

Affiliation at the time of contribution to this study.

Corresponding Author: Janki M. Desai; AbbVie Inc.; Clinical Pharmacology; 1 North Waukegan Road, Dept. R4PK, Bldg. AP31-3; North Chicago, IL; OFFICE: +18479356588; EMAIL: janki.m.desai@abbvie.com; clinpharm.publications@abbvie.com

Table S1. Treatment-Emergent Adverse Events Reported by one or more Participants Administered Midazolam Alone (Study 1A, Period 1/Day 1) and in combination with Limnetrelvir (Study 1A, Period 2/Day 10).

	Period 1 Time Segment 1 (N =12) n (%)	Period 2 Time Segment 2 (N =12) n (%)	Period 2 Time Segment 3 (N =12) n (%)	Overall (N =12) n (%)
Participants with treatment emergent adverse event (AE)	1 (8.3)	2 (16.7)	2 (16.7)	5 (41.7)
AE with reasonable possibility of being related to study treatment	1 (8.3)	2 (16.7)	2 (16.7)	5 (41.7)
Severe AE	0	0	0	0
Serious AE	0	0	0	0
AE leading to withdrawal of study treatment	0	0	0	0
AE resulting in death	0	0	0	0
All deaths	0	0	0	0

Note:

Period 1 Time Segment 1: Single dose of 1 mg midazolam from Period 1 Day 1 through Period 2 Day -1.

Period 2 Time Segment 2: Multiple doses of limnetrelvir QD 400 mg from Period 2 Day 1 to Day 9.

Period 2 Time Segment 3: Limnetrelvir QD 400 mg + 1 mg midazolam from Period 2 Day 10 to end of study.

Table S2. Treatment-Emergent Adverse Events Reported by one or more Participants Administered Midazolam Alone (Study 1B, Period 1/Day 1) and in combination with Limnetrelvir (Study 1B, Period 2/Day 5).

	Period 1 Time Segment 1 (N =12) n (%)	Period 2 Time Segment 2 (N =12) n (%)	Period 2 Time Segment 3 (N =12) n (%)	Overall (N =12) n (%)
Participants with treatment emergent adverse event (AE)	2 (16.7)	2 (16.7)	1 (8.3)	4 (33.3)
AE with reasonable possibility of being related to study treatment	2 (16.7)	2 (16.7)	1 (8.3)	4 (33.3)
Severe AE	0	0	0	0
Serious AE	0	0	0	0
AE leading to withdrawal of study treatment	0	0	0	0
AE resulting in death	0	0	0	0
All deaths	0	0	0	0

Note:

Period 1 Time Segment 1: Single dose of 1 mg midazolam from Period 1 Day 1 through Period 2 Day -1.

Period 2 Time Segment 2: Multiple doses of limnetrelvir QD 200 mg from Period 2 Day 1 to Day 4.

Period 2 Time Segment 3: Limnetrelvir QD 200 mg + 1 mg midazolam from Period 2 Day 5 to end of study.

Table S3. Treatment-Emergent Adverse Events Reported by one or more Participants Administered Limnetrelvir Alone (Study 2, Period 1/Day 1) and in combination with Itraconazole (Study 2, Period 2/Day 4).

	Period 1 Time Segment 1 (N =12) n (%)	Period 2 Time Segment 2 (N =12) n (%)	Period 2 Time Segment 3 (N =12) n (%)	Overall (N =12) n (%)
Participants with treatment emergent adverse event (AE)	5 (41.7)	1 (8.3)	2 (16.7)	5 (41.7)
AE with reasonable possibility of being related to study treatment	2 (16.7)	1 (8.3)	2 (16.7)	3 (25.0)
Severe AE	0	0	0	0
Serious AE	0	0	0	0
AE leading to withdrawal of study treatment	0	0	0	0
AE resulting in death	0	0	0	0
All deaths	0	0	0	0

Note:

Period 1 Time Segment 1: Single dose of limnetrelvir 50 mg QD from Period 1 Day 1 (Day 1 to 4).

Period 2 Time Segment 2: Multiple doses of itraconazole 200 mg as monotherapy in Period 2 (BID on Day 1 and QD on Day 2 - 3).

Period 2 Time Segment 3: Single dose of limnetrelvir 50 mg QD in Period 2 Day 4 in combination with multiple doses of Itraconazole 200 mg QD at Day 4 – 6 to end of study.